Skip to main content
Fig. 4 | BMC Immunology

Fig. 4

From: Characteristics of the specific humoral response in patients with advanced solid tumors after active immunotherapy with a VEGF vaccine, at different antigen doses and using two distinct adjuvants

Fig. 4

IgG seroconversion studies in patients that completed the trial vaccination scheme. a Seroconverted patients (individual that has shown two or more samples positive for VEGF-specific IgG antibodies), according to the different vaccination cohorts. b Early seroconversion: seroconverted patient with positive serum sample at week 5 (VSSP-adjuvanted cohorts) or week 6 (aluminum-adjuvanted cohorts)

Back to article page

BMC Immunology

ISSN: 1471-2172

Contact us